Background and objective: The association between angiotensin-converting enzyme (ACE) insertion/deletion (I/D) gene polymorphism and end-stage renal disease (ESRD) risk is still controversial. A meta-analysis was performed to evaluate the association between ACE I/D gene polymorphism and ESRD susceptibility. Method: A predefined literature search and selection of eligible relevant studies were performed to collect data from electronic databases. Results: Thirty-four articles were identified for the analysis of an association between ACE I/D gene polymorphism and ESRD risk. Both D allele and DD genotype were associated with ESRD susceptibility in overall populations (D: OR = 1.20, 95% CI: 1.06-1.36, p = 0.003, DD: OR = 1.47, 95% CI: 1.20-1.78, p = 0.0001) and in East Asians (D: OR = 1.34, 95% CI: 1.06-1.69, p = 0.01, DD: OR = 2.01, 95% CI: 1.29-3.12, p = 0.002). Only the DD genotype had a positive association with ESRD susceptibility in Caucasians (OR = 1.20, 95% CI: 1.01-1.43, p = 0.03). The result from sensitivity analysis in overall populations or Caucasians was similar to those in non-sensitivity analysis, but not among East Asians.
Introduction
End stage renal disease (ESRD) represents a clinical condition in which there has been an irreversible loss of endogenous renal function. 1 ESRD is an increasing problem worldwide 2 and is a major health problem associated with very high morbidity and mortality. 3 Patients with ESRD must receive a kidney transplant or live on dialysis. 4 Patients with ESRD display enhanced genomic damage, and DNA repair gene polymorphisms may affect DNA repair capacity and modulate susceptibility to ESRD. 5 Some investigations [6] [7] [8] suggested that genetic factors might play a key role in the onset of ESRD.
The angiotensin-converting enzyme (ACE) insertion/ deletion (I/D) gene polymorphism is a 287-bp sequence of DNA in the intron 16 of the ACE gene. 9 The ACE gene consists of either an insertion (I) allele or a deletion (D) allele that form three possible genotypes: II, ID or DD. 10 In adults plasma ACE does not change with age and is only to a minor extent influenced by environmental or lifestyle factors. 11 Compared with II homozygotes, circulating ACE levels in plasma were nearly 30% and 60% higher in ID heterozygotes and DD homozygotes, respectively. 11 Moreover, DD homozygotes also have higher tissue levels of ACE. 11 The ACE I/D gene polymorphism, correlating with circulating ACE concentration, 12, 13 has been implicated in the etiology of ESRD and has been investigated in numerous epidemiologic studies at present. However, the available evidence reported to date is weak because of sparseness of data or disagreements among studies. There have been limited attempts to explore the association of ACE I/D gene polymorphism with ESRD risk. We performed this meta-analysis from all published reports in English to investigate the relation between ACE I/D gene polymorphism and ESRD susceptibility, with the intention to provide a much more reliable finding on the significance of the association.
Materials and methods

Search strategy
The relevant studies were screened from the search engines of PubMed, Embase and Cochrane Library on 1 March 2012. The following terms in English were used to complete the search: "end-stage renal disease," "ESRD," "endstage renal failure," "ESRF," "angiotensin-converting enzyme," "ACE," and "gene." The search in PubMed was limited to humans and the English language. We also extended the search spectrum to "related articles" and the bibliographies of all retrieved studies. If multiple publications of the same data from the same study group occurred, we recruited only the later paper for analysis.
Inclusion and exclusion criteria
Inclusion criteria: (1) a case-control study; (2) the outcome had to be ESRD; (3) there had to be at least two comparison groups (ESRD group vs control group).
Exclusion criteria: (1) review articles, editorials and case reports; (2) articles did not provide the detailed genotype data; (3) investigating the association of other genes with ESRD; (4) investigating the role of ACE inhibitors in diseases; (5) multiple publications of the same data from the same study group.
Data extraction and synthesis
The following information was extracted from each study independently by at least two investigators: first author's surname, year of publication, ethnicity of study population, and the number of cases and controls for ACE genotype. Frequencies of D allele were calculated for each case group and control group, from the corresponding genotype distribution. The results were compared and disagreements were resolved by discussion.
Statistical analysis
Available data was entered into Cochrane Review Manager (RevMan, version 5) and analyzed. The pooled statistic was counted using the fixed-effects model, but a random-effects model was conducted when the p value of heterogeneity test was less than 0.1. 14 Results were expressed with odds ratios (ORs) for dichotomous data, and 95% confidence intervals (CIs) were also calculated. A p value of < 0.05 was required for the overall OR to be deemed statistically significant. 15 I 2 was used to test the heterogeneity among the included studies. We classified the investigations into studies for Caucasians, East Asians and Turkish populations because genotype frequencies and prevalence of ESRD were different among ethnic groups. In order to avoid excessive comparisons, the OR was calculated by using three methods: 16 method 1, allele comparison (D allele vs I allele); method 2, comparing DD homozygous with the other two combinations (DD vs ID+II); method 3, comparing II genotype with the other two combinations (II vs ID+DD). A Chi-square test using a web-based program was applied to determine if genotype distribution of the control populations reported conformed to the Hardy-Weinberg equilibrium (HWE) (HWE; p < 0.05 was considered significant). Sensitivity analysis was performed when studies with controls were not in the HWE. The Begg adjusted rank correlation test 17 was used for exploring publication bias (p < 0.1 was considered significant) when the sample number was more than 10. All descriptive data were expressed as mean ± SD.
Results
Study characteristics
The search yielded 287 references, 187 in PubMed, 93 in Embase and seven from Cochrane Library. According to the inclusion and exclusion criteria, 34 articles were identified for the analysis of the association between ACE I/D gene polymorphism and ESRD susceptibility in our review ( Figure 1 ). Seventeen studies [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] were conducted in Caucasians, 16 investigations [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] [46] [47] [48] [49] [50] in East Asians, and one 51 in a Turkish population. The data of our interest were extracted and are shown in Table 1 . These 34 studies contained 4446 case series and 7647 controls. The average frequency of ACE D allele was 56.53% in Caucasian ESRD patients, and 55.11% in controls. For East Asians, the average frequency of D allele was 38.46% in case groups, and 33.23% for controls. The frequency of D allele in the Turkish population was 65.38% in cases and 56.90% for the control group. When compared with that in Caucasians, the ratio of cases/controls for average frequency of D allele was markedly elevated in East Asians and in the Turkish population (East Asians: cases/controls = 1.16; Turkish population: cases/controls = 1.15; Caucasians: cases/controls = 1.03).
Association of the ACE gene polymorphisms with ESRD risk
In this meta-analysis, a significant association between D allele/DD genotype and ESRD risk was observed in overall populations (Figure 2 for D allele and Figure 3 for DD genotype; Table 2 ). However, the II genotype might not be a protective factor against the risk of ESRD in overall populations ( Table 2) .
Ethnic and geopolitical differences might affect the results of our analysis for the association of ACE I/D gene polymorphism with ESRD susceptibility. In order to evaluate this effect, we divided the population by ethnicity. D allele/DD genotype was associated with the risk of ESRD in East Asians (Table 2 ). Furthermore, there was an association between DD genotype and ESRD susceptibility in Caucasians (Table 2 ). However, the association of D allele with ESRD risk in Caucasians was not observed ( Table 2 ). In addition, II genotype might not be a protective factor against the risk of ESRD in Caucasians and East Asians ( Table 2 ). In the Turkish population, ACE I/D gene polymorphism was not associated with ESRD susceptibility ( Table 2) .
Sensitivity analysis
Eight studies (three 19, 21, 23 of Caucasians, four 42, 43, 45, 46 of East Asians and one 51 of a Turkish population) in which the genotype distributions in the controls significantly deviated from the HWE were excluded from our sensitivity analysis.
In the sensitivity analysis for overall populations, we found that the results were similar to those in the non-sensitivity analysis. A significant association between D allele/ DD genotype and ESRD risk was observed in overall populations, and II genotype might be no a protective factor against the risk of ESRD in overall populations ( Table 2) .
In Caucasians, the results of the sensitivity analysis were similar to those of the non-sensitivity analysis ( Table 2) . However, the results of the sensitivity analysis in East Asians were different from those of the non-sensitivity analysis ( Table 2 ). In our sensitivity analysis, we found that D allele/DD genotype was not associated with ESRD risk in East Asians (Table 2) . Interestingly, the result for II genotype in the sensitivity analysis was consistent with that of the non-sensitivity analysis in East Asians ( Table 2) .
Testing for publication bias for the analysis of association of ACE I/D gene polymorphism and ESRD susceptibility
There was no significant publication bias in overall populations (p = 0.286, Figure 4 (a)), in Caucasians (p = 0.837, ) and in East Asians (p = 1.000, Figure 4(c) ). In the sensitivity analysis, there was no significant publication bias in the overall populations (p = 0.758), in Caucasians (p = 0.827) or in East Asians (p = 0.537).
Discussion
In the past decades, D allele and DD homozygote had been reported to be associated with elevated plasma ACE levels. The increased level of ACE is associated with the pathogenesis of renal diseases. ESRD is a major health problem associated with very high morbidity and mortality, 3 and data on the risk factors for the pathogenesis of ESRD are insufficient. 52 This meta-analysis was performed to explore whether the ACE I/D polymorphism could predict the susceptibility of ESRD.
In this investigation, 34 suitable studies were recruited into our meta-analysis, 17 investigations of Caucasians, 16 studies in East Asians, and one study of a Turkish population. Our meta-analysis showed that the D allele and DD homozygote were associated with the onset of ESRD in overall populations, but II genotype was not. In our metaanalysis, sensitivity analysis was also performed in order to draw a robust conclusion. We found that the results from the sensitivity analysis were similar to those of the non-sensitivity analysis for overall populations. There was no significant publication bias in overall populations, including non-sensitivity analysis and sensitivity analysis. As mentioned above, we might draw the conclusion that the D allele and DD genotype were associated with ESRD susceptibility in overall populations. Geographical and ethnic difference factors might affect the association of gene polymorphism with ESRD risk. In our study, we found that the average frequency of D allele in controls was 55.11% in Caucasians. Furthermore, the frequency of D allele in the Turkish population was 56.90% for the control group. However, for East Asians, the average frequency of D allele for controls was 33.23%. The disequilibrium of D allele distribution in controls was observed among those different races. The subgroup analysis was conducted to explore the association of ACE I/D polymorphism with the susceptibility of ESRD in different races.
In Caucasians, there was an association between DD genotype and ESRD susceptibility. However, the association of D allele/II genotype with ESRD risk in Caucasians was not observed. Sensitivity analysis according to the HWE test was performed, and we found that the results from the sensitivity analysis were similar to those in the non-sensitivity analysis in Caucasians. There was no significant publication bias in Caucasians, including non-sensitivity analysis and sensitivity analysis. As mentioned above, we might draw the conclusion that DD genotype was associated with ESRD susceptibility in Caucasians.
In East Asians, there was an association between D allele/DD genotype and the risk of ESRD. The ratio of cases/controls for average frequency of D allele was elevated in East Asians (cases/controls = 1.16). D allele/DD genotype might be a risk factor to predict the risk of ESRD in East Asians. However, the results from the sensitivity analysis were inconsistent with those from the non-sensitivity analysis. In the sensitivity analysis, D allele/DD genotype was not associated with the risk of ESRD in East Asians. Although there was no significant publication bias in the non-sensitivity analysis and sensitivity analysis for East Asians, heterogeneity among the included studies was not improved in the sensitivity analysis. More well-designed studies should be performed in the future. It is difficult, therefore, to draw a robust conclusion of the association 
between ACE I/D polymorphism and susceptibility of ESRD.
For the Turkish population, ACE I/D polymorphism was not associated with the susceptibility of ESRD. However, there was only one study recruited for a Turkish population in this meta-analysis, and the gene distribution of the controls was not in the HWE. The conclusion for the Turkish population might be less robust. However, in this study, we found that the ratio of cases/controls for frequency of D allele was elevated in the Turkish population (cases/controls = 1.15). To determine whether there is an association between ACE I/D polymorphism and the susceptibility of ESRD, more vigorous studies should be performed in the future.
DD genotype was associated with increased ACE level. 11 In this meta-analysis, we found that there was a significant association of the DD gene with ESRD risk in Caucasians and East-Asians, but this association was not found for the Turkish population. We speculate that the reasons are as follows: First, in different races, the sensibility of ACE level for ESRD disease was different. Second, the sample size of included studies for this meta-analysis in different populations was different. The sample size for Caucasians/ East Asians was larger than that of the Turkish population.
Some reports have only 11% or 14% DD genotype in the whole population, hence the DD genotype is less important and the II genotype may be more reflective of the actual state of events in such populations. In this meta-analysis, we found that the II genotype was not associated with the risk of ESRD in overall populations, Caucasians, East Asians and the Turkish population. To determine whether II genotype could not play a protective role against ESRD, more studies should be performed in the future.
There were some studies reporting that ACE inhibitor (ACEI) and angiotensin receptor blocker (ARB) therapy might influence the association of ACE I/D gene polymorphism with ESRD risk. Interestingly, Woo et al. 44 performed a randomized controlled trial in patients with IgA nephritis (IgAN) who were followed up for five years to determine their long-term renal outcome to ACEI/angiotensin receptor antagonist (ATRA) therapy and to ascertain if their ACE gene profile could play a role in determining their response to therapy. They found that, among patients with genotype II, there were fewer cases of ESRD in the treatment group when compared to the untreated control group, and the advantage of therapy was not seen in patients with ID or DD genotypes. Furthermore, Woo et al. 45 also performed an interesting study to investigate the effect of high-dose ARB in IgAN patients and found that patients, treated with high-dose ARB, irrespective of ACE gene polymorphism DD, ID or II, would still respond with more effective reduction of proteinuria and retard progression to ESRD. Treatment using ACEI/high-dose therapy may confer the additional benefit of early improvement in renal function in some patients with the genomic effect. More studies should be performed to confirm this in the future. In our meta-analysis, some of the included studies mentioned the administration of drugs for the ESRD patient. However, most of the included studies did not show the data of the gene distribution of ACE in ESRD patients treated with drugs. We could not perform a multivariate analysis to look for various confounding factors. More studies providing the data of the gene distribution of ACE in the ESRD patients treated with drugs should be performed in the future.
In the past years, there were some meta-analyses to explore the association of the ACE I/D gene polymorphism with the susceptibility of ESRD in patients with autosomal dominant polycystic kidney disease (ADPKD) 53 and in patients with diabetic nephropathy (DN). 54 Pereira et al. 53 performed a meta-analysis to explore the relationship between the ACE I/D gene polymorphism with the progression of renal failure in patients with ADPKD and found that the ACE I/D gene polymorphism was not associated with the progression of renal failure in overall populations, Caucasians and Asians. Yu et al. 54 performed a meta-analysis to study the association of the ACE I/D gene polymorphism with ESRD risk in DN patients, and reported that there was a notable association between D allele or DD genotype and ESRD susceptibility in overall populations. Furthermore, in their sub-group analysis according to ethnicity, D allele or DD genotype was associated with ESRD risk in Asians, and the association of DD genotype with ESRD risk was observed in Caucasians. We also performed the meta-analysis according to the underlying diseases and found that the results of the association of ACE I/D gene polymorphism with ESRD risk in ADPKD patients and in DN patients were consistent with those of Pereira et al. 53 and Yu et al. 54 (data not shown). In this meta-analysis, we mainly explored the relationship between ACE I/D gene polymorphism and ESRD risk, but not sub-group diseases.
In our investigation, we found that D allele or DD genotype was associated with ESRD susceptibility in overall populations, and DD genotype was associated with ESRD susceptibility in Caucasians, and these results were consistent with those from sensitivity analysis. The D allele or DD genotype was associated with ESRD susceptibility in East Asians, but the results were inconsistent with those from non-sensitivity analysis. More studies in East Asians should be performed in the future. D allele or DD genotype might be more valuable genetic molecular markers to predict the burden of ESRD in overall populations rather than in any single individual. However, these findings should be regarded cautiously because many other factors, such as heterogeneity of enrolled cases, limited statistical power, variable study designs and different interventions, were closely related to affect the results. Furthermore, whether the I/D polymorphism is just linked with other discrete loci involved in the occurrence of ESRD is not clear at the moment. Undoubtedly, the limitations mentioned above might affect our final conclusions.
In this meta-analysis, we also performed a further sensitivity analysis by sequential omission of individual cohorts. 55 We found that the results for the association of ACE I/D gene polymorphism with ESRD susceptibility from the sensitivity analysis were consistent with the nonsensitivity analysis (data not shown). The results from our study might be more robust to some extent. However, more studies also should be performed in the future. Furthermore, this meta-analysis did not include many other genetically distinct human populations (e.g. patients of African, Arab, Native American or Australian Aboriginal ancestry), driven by the lack of publications on these populations. Study on the association of ACE I/D gene polymorphism with ESRD risk should be performed in these populations.
In conclusion, the results of our study support that D allele or DD genotype was associated with ESRD susceptibility in overall populations, and DD genotype was associated with ESRD susceptibility in Caucasians. However, more case-control association investigations on larger, stratified populations are required to further clarify the role of this ACE I/D gene polymorphism in ESRD susceptibility in different ethnicities. 
